Saturday 17 October 2026
Export MESO’s income statement to Excel — free account
Mesoblast Limited
MESO Healthcare Biotechnology
Mesoblast Limited’s revenue for fiscal 2026 (year ended June 2026) was $120.3 million, up 599.2% from fiscal 2025. Insiders bought in the last twelve months.
13.28
0.67
−4.80%
Follow MESO
| Jun '17 | Jun '18 | Jun '19 | Jun '20 | Jun '21 | Jun '22 | Jun '23 | Jun '24 | Jun '25 | Jun '26 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
1 | 4 | 1 | 6 | 2 | 4 | 3 | 3 | 4 | 5 |
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z-Score |
1.60 | 1.18 | 0.45 | 2.67 | 1.81 | (0.84) | 0.24 | (0.05) | 2.26 | 3.40 |
P/S ratio |
263.05 | 32.49 | 29.86 | 37.46 | 121.40 | 28.22 | 81.08 | 70.30 | 112.91 | 140.28 |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
1.54 | 2.23 | (0.11) | 0.44 | 0.58 | (1.05) | (1.09) | (2.28) | (0.67) | (0.89) |
Beneish M-Score |
— | 0.22 | 0.18 | (2.87) | — | — | — | (2.44) | (1.48) | 2.37 |
P/Operating CF |
(27.07) | (27.91) | (26.16) | (61.52) | (47.84) | (20.74) | (37.36) | (32.39) | (41.00) | (34.68) |
P/B ratio |
1.23 | 1.03 | 1.04 | 2.19 | 1.56 | 0.58 | 1.21 | 1.04 | 1.84 | 1.83 |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | 1,063.66 | 0.00 | 0.00 | 0.00 | 0.00 | 178.83 |
EV/Sales |
244.08 | 33.74 | 31.71 | 36.22 | 115.68 | 31.76 | 86.07 | 75.39 | 123.70 | 139.87 |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
(6.17) | (7.80) | (9.17) | (20.67) | (8.56) | (4.93) | (10.20) | (7.48) | (13.32) | (12.56) |
EV/FCF |
(6.13) | (7.76) | (9.10) | (19.87) | (8.41) | (4.91) | (10.15) | (7.45) | (13.25) | (12.44) |
Quick Ratio |
1.35 | 3.67 | 1.23 | 1.45 | 1.50 | 1.26 | 1.87 | 1.15 | 1.72 | 1.98 |
Current Ratio |
1.73 | 4.21 | 1.41 | 1.51 | 1.57 | 1.36 | 1.95 | 1.18 | 1.99 | 2.43 |
Net Debt/EBITDA |
0.53 | (0.35) | (0.36) | 0.57 | 0.50 | (0.52) | (0.65) | (0.85) | 0.55 | (0.67) |
Debt/Assets |
0.00% | 8.58% | 12.46% | 12.20% | 12.66% | 14.59% | 16.25% | 17.09% | 15.53% | 15.42% |
Debt/Equity |
0.00 | 0.11 | 0.17 | 0.16 | 0.16 | 0.19 | 0.22 | 0.24 | 0.20 | 0.21 |
Asset Turnover |
0.00 | 0.03 | 0.02 | 0.05 | 0.01 | 0.01 | 0.01 | 0.01 | 0.02 | 0.15 |
Operating CF/Net income |
1.24 | 2.13 | 0.64 | 0.72 | 1.02 | 0.72 | 0.77 | 0.55 | 0.49 | 0.76 |
Capex/Depreciation |
(0.10) | (0.08) | (0.13) | (0.61) | (0.39) | (0.05) | (0.08) | (0.07) | (0.11) | (0.10) |
Interest Coverage |
(188.98) | (35.07) | (7.72) | (5.19) | (8.30) | (4.30) | (3.08) | (2.83) | (3.43) | (1.39) |
| (14.70%) | (6.64%) | (17.49%) | (15.13%) | (17.48%) | (16.94%) | (16.40%) | (17.91%) | (18.95%) | (9.86%) | |
| (11.47%) | (5.24%) | (13.36%) | (11.25%) | (13.37%) | (12.99%) | (12.30%) | (13.14%) | (14.05%) | (7.38%) | |
ROIC |
(11.97%) | (7.06%) | (10.67%) | (8.99%) | (10.31%) | (8.71%) | (7.18%) | (7.66%) | (8.83%) | (3.53%) |
Return on Tangible Assets |
(267.15%) | (45.16%) | (472.20%) | (160.05%) | (173.43%) | (445.40%) | (199.57%) | (613.96%) | (98.76%) | (48.65%) |
Average Days of Receivables |
566.42 | 1,060.12 | 88.62 | 17.87 | 237.03 | 157.39 | 340.52 | 1,295.74 | 315.51 | 175.02 |
Research and Development Expense of Revenue |
2,442.54% | 380.18% | 357.70% | 174.74% | 711.00% | 321.37% | 362.47% | 672.92% | 202.39% | 81.09% |
Selling, General and Administrative Expense of Revenue |
953.86% | 126.33% | 129.32% | 79.64% | 413.99% | 301.21% | 338.27% | 423.25% | 228.57% | 47.69% |
Intangible Assets out of Total Assets |
0.89 | 0.84 | 0.89 | 0.79 | 0.78 | 0.87 | 0.86 | 0.86 | 0.73 | 0.73 |
Share Based Compensation of Revenue |
218.74% | 35.75% | 26.12% | 23.39% | 167.78% | 54.22% | 48.73% | 99.46% | 128.43% | 12.37% |
Graham Net Nets |
(0.12) | (0.08) | (0.22) | (0.04) | (0.02) | (0.33) | (0.14) | (0.14) | (0.14) | 0.00 |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Earnings Yield |
(12.08%) | (6.12%) | (18.02%) | (6.41%) | (10.96%) | (31.53%) | (14.32%) | (16.52%) | (10.28%) | (8.28%) |
Free Cash Flow Yield |
(15.13%) | (13.38%) | (11.67%) | (4.87%) | (11.33%) | (22.93%) | (10.45%) | (14.39%) | (8.27%) | (8.02%) |
Revenue per Share |
0.06 | 0.37 | 0.34 | 0.61 | 0.12 | 0.16 | 0.10 | 0.06 | 0.14 | 0.93 |
Operating CF per Share |
(2.39) | (1.61) | (1.17) | (1.07) | (1.67) | (1.01) | (0.81) | (0.49) | (0.41) | (0.34) |
Capex per Share |
(0.01) | 0.00 | (0.01) | (0.04) | (0.03) | 0.00 | 0.00 | 0.00 | (0.01) | (0.01) |
Free Cash Flow per Share |
(2.40) | (1.62) | (1.17) | (1.11) | (1.69) | (1.02) | (0.82) | (0.49) | (0.42) | (0.35) |
Cash per Share |
1.15 | 0.81 | 1.02 | 2.45 | 2.26 | 0.93 | 0.92 | 0.64 | 1.34 | 0.79 |
Shareholders Equity per Share |
12.95 | 11.72 | 9.73 | 10.39 | 9.61 | 7.66 | 6.45 | 4.87 | 4.95 | 4.39 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
12.95 | 11.72 | 9.73 | 10.39 | 9.61 | 7.66 | 6.45 | 4.87 | 4.95 | 4.39 |
Free Cash Flow |
(95.78) | (75.21) | (58.07) | (58.61) | (102.40) | (66.01) | (63.58) | (48.79) | (50.68) | (44.73) |
Working Capital |
26.94 | 77.07 | 18.19 | 46.41 | 53.95 | 18.46 | 39.68 | 13.22 | 101.72 | 116.38 |
Capital Expenditures |
(0.31) | (0.20) | (0.28) | (2.25) | (1.65) | (0.23) | (0.31) | (0.33) | (0.73) | (0.90) |
Net Current Asset Value |
(75.31) | (45.36) | (108.54) | (47.73) | (15.09) | (95.26) | (85.92) | (102.33) | 17.11 | (7.18) |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.13 | 0.01 | 0.02 | 0.07 | 0.22 | 0.02 | 0.04 | 0.06 | 0.04 | 0.01 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
1.69 | 2.44 | 2.59 | 1.60 | 1.41 | 2.14 | 3.03 | 4.22 | 3.76 | 4.72 |
Cash ROIC |
(17.03%) | (11.69%) | (9.48%) | (7.63%) | (12.60%) | (10.09%) | (9.32%) | (7.42%) | (5.75%) | (5.66%) |
Accounts Receivable Turnover |
0.62 | 0.64 | 0.61 | 11.42 | 2.32 | 2.21 | 1.32 | 0.42 | 0.96 | 3.32 |
Accounts Payable Turnover |
0.49 | 0.27 | 0.96 | 1.33 | 1.47 | 1.28 | 1.28 | 1.16 | 0.39 | 0.51 |
Inventory Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.66 |
Average Days of Payables |
659.66 | 1,253.84 | 310.39 | 360.14 | 218.63 | 309.59 | 265.13 | 164.19 | 1,357.69 | 1,025.03 |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1,582.81 | 615.62 |
Average Receivables |
3.90 | 27.05 | 27.21 | 2.82 | 3.21 | 4.62 | 5.70 | 13.98 | 17.91 | 36.26 |
Average Payables |
24.48 | 20.36 | 15.99 | 19.02 | 22.29 | 21.34 | 21.61 | 13.61 | 13.08 | 32.94 |
Average Inventory |
— | — | — | — | — | — | — | — | — | 25.18 |
Average Assets |
669.85 | 674.06 | 672.28 | 692.86 | 739.16 | 703.43 | 665.78 | 669.28 | 726.92 | 778.88 |
Average Common Equity |
522.46 | 531.39 | 513.53 | 515.19 | 565.36 | 539.22 | 499.44 | 491.10 | 538.90 | 582.92 |
Columns are period end dates